Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Dambrava, G. Peñarroja, I. Aldabo, E. Mallorca, O. Sibila, M. A. Marcos, M. Camps, M. Sánchez, C. Agusti, J. Mensa, A. Torres (Barcelona, Spain). Are corticosteroids useful in community-acquired pneumonia?. Eur Respir J 2006; 28: Suppl. 50, 3074

Member's Comments

No comment yet.

Related content which might interest you: Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Respiratory infections in the immunocompetent host: from asthma exacerbations to hospital-acquired pneumonia Source: Annual Congress 2007 - Infections year in review Year: 2007 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Corticosteroids for community-acquired pneumonia: are we still there? Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Mixed community-acquired pneumonia in hospitalised patients Source: Eur Respir J 2006; 27: 795-800 Year: 2006 Japanese guidelines for the management of community-acquired pneumonia: differential diagnosis of atypical pneumonia and bacterial pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010